Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer

Namikawa, Tsutomu; Ishida, Nobuko; Tsuda, Sachi; Fujisawa, Kazune; Munekage, Eri; Iwabu, Jun; Munekage, Masaya; Uemura, Sunao; Tsujii, Shigehiro; Tamura, Takahiko; Yatabe, Tomoaki; Maeda, Hiromichi; Kitagawa, Hiroyuki; Kobayashi, Mariko; Hanazaki, Kazuhiro

doi:10.1007/s10120-018-0897-8

Cited by 72 publications

(62 citation statements)

References 30 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies identified that increased ALP level is correlated with some advanced cancer status. 13,14 Since Chan et al 15 firstly reported the ratio of ALB to ALP combined with ALB and ALP levels can be used as an indicator for predicting the prognosis for patients with liver cancer, and such prediction ability is higher than that based on ALB or ALP levels alone, more studies began to investigate these indicators in other types of cancer. [7][8][9][10][16][17][18][19][20][21] Li et al 16 firstly reported that the relationship between AAPR and OS after investigating 290 stage IV NSCLC patients, finding that AAPR was an independent predictor of OS in multivariate analysis (HR = 0.657, 95% CI = 0.504-0.856, P < .01).…”

Section: Discussionmentioning

confidence: 99%

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Objectives To investigate the relation between AAPR and OS in patients with advanced non‐small cell lung cancer (NSCLC). Methods A retrospective cohort study was conducted with 808 patients with advanced NSCLC who were treated in Guangxi Medical University Affiliated Tumor Hospital in China from 5 March 2009 to 31 August 2018. The target‐independent and dependent variables were AAPR measured in patients before anticancer treatment and overall survival (OS), respectively. Covariates involved in this study included age, gender, ECOG status, smoking history, clinical stages, pathological type, driver mutation (EGFR or ALK), metastasis or not (bone, lung, liver, brain, malignant plural effusion, and other organs), number of organ metastasis(≤3, >3), first‐line regiment and number of treatment lines (≤3, >3). Results The mean age of the selected patients was 58.3 ± 10.9 years and 68.6% were male. We divided patients according to their AAPR into low (AAPR < 0.34, n = 266), medium (AAPR = 0.34‐0.47, n = 259), and high (AAPR > 0.47, n = 283) tertile groups. Medium and high AAPR were associated with a decreased risk of death after fully adjusted Cox proportional hazard model(s) with hazards ratio (HR) 0.77 (95%CI = 0.58‐1.03) and HR 0.59 (95%CI = 0.45‐0.78), respectively (P for trend <.05). The median OS of low, medium, and high AAPR was 9.3, 11.8, and 16.9 months, respectively (P value <.0001). No optimal cutoff value of AAPR for prognosing OS was identified by smooth curve fitting. The HR and the 95% confidence intervals of the left and right sides of the inflection point 0.6 as cutoff value were 0.28 (95%CI = 0.14‐0.57) and 0.77 (95%CI = 0.34‐1.73), respectively (P value = .127). By subgroup analysis, similar results were consistently observed across nearly all the subgroups. Conclusion Our study implied that pretreatment AAPR can be used as an independent prognostic factor in patients with advanced NSCLC. This ratio should be applied for risk stratification and clinical decision‐making in those patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A meta-analysis investigating the prognostic value of the LDH level in solid tumors showed that a high LDH level is associated with poor survival in melanoma, gastric, lung cancer, prostate, and renal cell carcinomas (34). Recently, a high LDH level has been demonstrated to effectively predict the response to cancer treatment, such as chemotherapy (11), anti-angiogenetic agents (35), and checkpoint immunotherapy (22,24) in various cancers. The prognostic role of the LDH level was also investigated in ESCC patients who underwent curative treatment in the study from Wei et al (23).…”

Section: Discussionmentioning

confidence: 99%

“…The inflammation process has been proposed to be an important feature in patients with malignant tumors (6), which is involved in the progression of tumorigenesis, disease development, and patient prognosis (7,8). Furthermore, some routinely tested blood parameters, such as neutrophil count, lymphocyte count, and lactate dehydrogenase (LDH) level, have been demonstrated as potential inflammatory biomarkers and have prognostic value in patients with cancers (9)(10)(11). Neutrophils are acknowledged as the first line of defense against inflammations and infections, as well as play an important role in the tumor microenvironment (TME) (12,13).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy

Luo

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: This present study aimed to explore the prognostic value of pretreatment neutrophil and lactate dehydrogenase (LDH) and to develop a prognostic risk scoring model to predict prognosis in esophageal squamous cell cancer (ESCC) patients treated with definitive radiotherapy. Methods: Retrospectively collected data of patients who received definitive radiotherapy for ESCC at Shantou Central Hospital between January 2009 and December 2015 were included for the analysis. The association between the level of LDH and neutrophil and clinicopathological characteristics were analyzed. We performed univariate and multivariate analyses to identify the prognostic predictors for patients with ESCC. Based on the results, we also developed a prognostic risk scoring model and assessed its predictive ability in the subgroups. Results: A total of 567 patients who received definitive radiotherapy for ESCC were included in the present study. The optimal cutoff values were 4.5 × 10 9 /L, 3.25, and 220 U/L for neutrophil, neutrophil-to-lymphocyte ratio (NLR), and LDH, respectively. A high level of LDH was significantly associated with advanced N stage (p = 0.031), and neutrophil count was significantly associated with gender (p = 0.001), T stage (p < 0.001), N stage (p = 0.019), clinical stage (p < 0.001), and NLR (p < 0.001). Multivariate survival analysis identified gender (p = 0.006), T stage (p < 0.001), N stage (p = 0.008), treatment modality (p < 0.001), LDH level (p = 0.012), and neutrophil count (p = 0.038) as independent prognostic factors for overall survival. Furthermore, a new prognostic risk scoring (PRS) model based on six prognostic factors was developed, in which the patients were divided into three groups with distinct prognosis (χ 2 = 67.94, p < 0.0001). Conclusions: Elevated baseline LDH level and neutrophil count predicted poor prognosis for ESCC patients treated with definitive radiotherapy. A PRS model comprised of LDH, neutrophil count, and other prognostic factors would help identify the patients who would benefit the most from definitive radiotherapy.

show abstract

“…Based on the results of the previous pivotal randomized phase III trials, adjuvant chemotherapy is usually performed after surgery, in order to circulate the anticancer drug(s) throughout the entire body via the bloodstream to control micrometastases and prevent recurrence [4,25,26]. Although postoperative adjuvant chemotherapy is effective in the survival of patients with locally advanced gastric cancer, approximately 20-30% of patients still develop recurrence [19][20][21][22][23][24][25][26][27][28]. The results of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) showed the median time from recurrence to death for recurrent gastric cancer patients was 11.4 months [26,28].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: The present study sought to evaluate host-related factors as predictors in patients receiving chemotherapy for recurrent advanced gastric cancer. Methods: Sixtythree patients were enrolled in the study and received chemotherapy for recurrent gastric cancer at the Kochi Medical School from 2008 to 2015. Clinicopathological information and systemic inflammatory response data were obtained retrospectively to investigate associations between baseline cancer-related prognostic variables and survival outcomes. Results: The median survival time was significantly higher for patients with a Glasgow prognostic score (GPS) of 0 compared to a GPS of 1 or 2 (18.2 vs. 7.1 months; p = 0.006), and for patients in the normal range for carbohydrate antigen-125 (CA125) compared to higher levels (17.9 vs. 4.1 months; p = 0.003). There was no significant influence on overall survival by age, gender, disease status, metastatic site, time to recurrence, carcinoembryonic antigen level, CA19-9 level, prognostic nutrition index, or neutrophil to lymphocyte ratio according to the results of the univariate log-rank tests. Multivariate survival analysis identified a GPS of 1 or 2 (hazard ratio, 3.520; 95% confidence interval, 1.343-9.227; p = 0.010) and a high CA125 level (hazard ratio, 3.135; 95% confidence interval, 1.276-7.697; p = 0.013) as significant independent predictors associated with a poorer prognosis in the studied group of cancer patients. Conclusions: A GPS of 1 or 2 and a high level of CA125 are independent predictors of a poorer prognosis in patients receiving chemotherapy for recurrent gastric cancer.

show abstract

Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer

Cited by 72 publications

References 30 publications

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer

Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy

Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer

Contact Info

Product

Resources

About